Recommended Cefepime Dose for Pseudomonas Urinary Tract Infection
For urinary tract infections caused by Pseudomonas aeruginosa in adults with normal renal function, use cefepime 2 g IV every 12 hours for 10 days. 1
Dosing Algorithm
Step 1: Assess Infection Severity and Renal Function
Mild to Moderate UTI (uncomplicated cystitis):
- Cefepime 0.5-1 g IV every 12 hours for 7-10 days 1
- However, this lower dose is NOT recommended for Pseudomonas infections
Severe UTI or Pyelonephritis due to Pseudomonas:
- Cefepime 2 g IV every 12 hours for 10 days 1
- This is the FDA-approved dose specifically for severe UTI caused by Pseudomonas
Alternative for Pseudomonas infections (any site):
- Cefepime 2 g IV every 8 hours may be used for Pseudomonas infections at other sites (pneumonia, bacteremia) 2
- Recent evidence suggests 2 g every 8 hours (6 g/day total) may be superior to 1 g every 6 hours (4 g/day total) for Pseudomonas bacteremia, with significantly lower mortality 3
Step 2: Adjust for Renal Impairment
CrCl 30-60 mL/min:
- 2 g IV every 24 hours 1
CrCl 11-29 mL/min:
- 1 g IV every 24 hours 1
CrCl <11 mL/min:
- 500 mg IV every 24 hours 1
Hemodialysis:
- 1 g on day 1, then 500 mg every 24 hours (administer after dialysis) 1
Continuous RRT:
- 2000 mg every 12 hours based on retrospective data showing 72.7% 30-day survival 4
Step 3: Consider Pharmacodynamic Optimization
The critical pharmacodynamic target for Pseudomonas infections is achieving >60% fT>MIC (percentage of time free drug concentration remains above the MIC) 5. Patients with fT>MIC ≤60% were 8.1 times more likely to experience microbiological failure 5.
To maximize probability of target attainment:
- Use at least 2 g every 8 hours for MICs approaching the susceptibility breakpoint (≥8 mcg/mL) 5
- Consider extended infusion (over 3 hours) for higher MICs, though this is extrapolated from carbapenem data 2
Key Clinical Considerations
Duration:
- Standard duration is 10 days for severe UTI/pyelonephritis 1
- May extend to 5-10 days for complicated UTI based on clinical response 2
Combination Therapy:
- Cefepime monotherapy is appropriate for susceptible Pseudomonas UTI 2
- Consider adding an aminoglycoside for critically ill patients or difficult-to-treat Pseudomonas (DTR-PA), though aminoglycoside monotherapy is acceptable for UTI 2
Common Pitfall: Avoid using the lower dose (1 g every 12 hours) for Pseudomonas infections, even if labeled for "mild to moderate" UTI. Pseudomonas requires the higher 2 g dose due to its intrinsically higher MICs and propensity for resistance development 1, 5.
Resistance Considerations: If the isolate is carbapenem-resistant Pseudomonas (CRPA) but cefepime-susceptible, cefepime 2 g every 8-12 hours remains appropriate 2. For difficult-to-treat Pseudomonas (DTR-PA), consider newer agents like ceftolozane-tazobactam or ceftazidime-avibactam 2.